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Editorial 
The Haunting of Medical Literature 
Bneann Miller, hfth-year i:tiarmacy student from Fairfield, Ohio, Tana Peterman, fifth-year pharmacy student from Jacksonville, N.C. 
Abstract 
Ghostwriting, or using the names of academic researchers to 
validate studies commissioned by pharmaceutical companies, has 
become a growing concern within medical literature. Omission from 
authorship of the names of individuals making considerable conllibu-
tions to a paper is one of the most significant aspects of ghostwrit-
ing. Policy prohibiting medical ghostwriting is lacking, and it is nearly 
impossible to prevent the practice without strict and thorough guide-
lines. More strict guidelines banning ghostwriting, denying govern-
ment funds to organ12at1ons without such policies, and development 
of databases to track offending authors and organizations could 
decrease the impact of ghostwnting in medical literature. 
Background 
Clinical evidence has come to be revered as the standard of truth in 
medical practX:e. Pharmacists turn to clinical literature to make sound 
recommendations for patient drug therapy. It 1s often ass urned that 
the integrity and validity of a published paper is ensured by referring to 
literature in esteemed, peer-reviewed journals. However, ethical con-
siderations and conflicts of int'lrest in authorship are slipping through 
quality assurance systems employed by these pumals and threatening 
the foundation of medicine. Ghostwriting, or using the names of aca-
demrc researchers to validate studies comm1ss1oned by pharmaceuncal 
companies, has become a growing concern within medical lrterarure.1 
Also concerning may be the use of publication planning, a form of 
systematically populating mec1cal literature on the corporate scale. 
Publication planning 1s conducted by a team of people employed by a 
pharmaceutical manufacturer in an attempt to control every possible 
aspect of public information available about a drug of interest.2 
PublicatJon plans include strategies for conducting explicit trials that 
yield desired results combined with the carefully timed release of 
information to specific target audiences. In some cases, the planning 
team may be more responsible for manuscripts submitted to medical 
pumals than the respected author(s) appearing on the page. 
Contributing Factors 
The first factor conrributing to medical ghostwriting is the definition of 
authorship. The correct protocol for listing authors 1s complicated by 
histoncal methods of listing authors alphabetically or l1Sting the head 
of department as lead author as a sign of respect.3 Currently, the 
International Committee ot Medical Journal Editors defines author-
ship as fulfilling allot the following criteria for authorship suootantial 
contnbutJon to conception anc design , acquisition of data, or analys1S 
and 1merpretat10n of data, drafting the article and/or revising 1t cntically 
for important intellectual content, and final approval of the version to 
be published.• Om1Ssion of the names of ind1v1duals making consider-
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able contributions to a paper from authorship is one of the 
most significant aspects of ghostwntmg. More importantly, with 
the title of author comes a responsibility to ensure that the 
paper's content, intent and findings are based on the results of 
the study and scientific principle and not skewed by financial 
or political gain.5 Authors list disclosure statements to inform 
the reader of existing conflicts of interest; however, the term 
"conftlct of interest' 1s difficult to define. These conflicts typically 
include employment, grants and other financial support, bur the 
lines become blurred when referring to patent nghts. per-
sonal relationships or political ties. When the true authors are 
excluded from publications, rhey cannot be held responsible tor 
the integrity of their work. 
Polley proh1b1ting medical ghostwntmg 1s lacking. In an evalu-
ation of 50 of the top academic medical centers m the United 
States, 52 percent had no published policy regarding author-
ship or ghostwritmg.1 Without a policy in pace, It IS nearly 
impossible to stop this type of unethical misconduct While the 
responsibility of honesty and disclosure lies with the author, 
there are few tools available for editors to police authorship va-
lidity 5 A mere 8.8 percent of pumals have a policy for verifying 
author claims and conflicts of interest. 6 
A case of Ghostwriting 
An example of ghostwriting that is thought to significantly 
impact the medical literature was when a oharmaceutJcal 
manufacturer attempted to prove that their drug could be used 
as an antidepressant in adolescents.7 This study's results were 
published 1n the Journal of the American Academy of Child 
and Adolescent Psychiatry and listed 22 authors. The idea for 
the study came from the primary author and was accepted and 
conducted by the pharmaceutical manufacturer However, the 
result of this study and similar studies showed no efficacy for 
the drug in adolescents compared to placebo. The manufactur-
er worried that the lack of efficacy in pediatrics would possibly 
make the medical community question the efficacy of the drug 
in general. Therefore, the manufacturer decided only to publish 
the positive findings from the study. A medical publishing com-
pany was hired to draft the positive information and prepare it 
for publicat10n. 
A synopsis of the clinical report was provided to the ghostwnter 
1n the medical publlshing group who used this shortened report 
to wnte the first draft of the manuscnpt. The ghostwnter also 
was found to have contributed to the article by developing and 
implementing a publication plan, responding to peer-reviews, 
and providing the primary author with drafts and cover letters. 
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Research looking into the communication between the listed authors and 
employees at the medical publishing company showed that many of the 
22 listed authors had little to no involvement with the article. The ghost-
wnter was actually the pnmary writer of the article drafts, even though 
not listed as such. Also, 1t was shown that the second and third authors 
made only minor edits to the articlg throughout the process. Many of the 
authors were shown to have only made small edits to one of the drans. 
having only assisted in running the study, or having made no recogniz-
able contribution at all.7 
A ma pr issue with the first draft was that there were noticeable dif-
ferences between it and the final clinical report, even though this was 
the source used to write the first draft. In the clinical report it is stated 
that only two primary outcomes were measured. In the first draft, eight 
primary outcomes were mentioned: four of these outcomes showed 
increased efficacy of the drug over placebo, which contradicts the 
findings of the srudy. Also, the line between the primary and secondary 
outcomes was blurred. After peer review, the article was edited again to 
include only the original two pnmary outcomes , but the information was 
presented in such a way that one of the outcomes appeared to be pos1-
t1ve and reinforced the Idea of efficacy for the drug. The side effects of 
the medication were inconsistent with the original report as well, and the 
seriousness of some listed side effects was not expressed.7 
The results of this study being published include many clinicians 
believing the drug to be an effective and highly tolerable medication 
for adolescents. In 207 articles published since 2008, this study was 
mentioned and used as evidence that the drug is effective for use in 
adolescents. Only 31 of these articles correctly presented the informa-
tion from the onginal study and showed slight skepticism over the results 
of thA puhlication.1 
Possible Solutions 
Strict defintt10ns of authorship need to be included in the policies of 
both medical pumals and academic medical centers. It 1s not enough 
to condemn ghostwn!lng; the term needs to be extensively defined to 
be enforceable.' ThlS strategy can further be amplified by government 
funding denying grants to 1nst1tut1ons that lack these stringent ethical 
policies. Enforcement of these policies could be further reinforced by 
purnals requiring listed article aut1ors to sign a statement guaranteeing 
the integrity of their article and holding them accountable if dishonesty 
is suspected.a If violation of these policies is proven, offenders could be 
punished by revoking government funding, refusing to publish subse-
quent works by the author, and enforcing legal responsibility for falsifying 
documents.' These exclusions could be made possible by compiling 
an online database for easy access to a list of an author or institution's 
ethical infractions.3 
Discussion 
Ghostwriting will not be stopped until all levels of medical publishing 
commit to higher standards for literary ethics. PractitJoners have a right 
to be informed of these conflicts of interest in literature so they can 
make their own decisions about the clinical validity of the evidence they 
are reading. Ghostwriting and publication planmng allow publication of 
biased or incomplete 1ntormat1on that may be harmful to patients who 
begin therapy with a medication with side effects and risks that are not 
fully disclosed. Many patients now may be suffering from severe adverse 
effects of medications because the dangers were not known and the 
treatment was marketed as being safe and effective. Ghostwriting is an 
emerging problem in medical writing that not only has ethical implica-
tions, but also affects patients and their wellbeing. The quality of medical 
care provided to patients is only as strong as the integrity of the literature 
that backs it. 
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